Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvimopan for Opioid-Induced Bowel Dysfunction in Cancer Pain
NCT00101998Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2003
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 2, randomised, double-blind trial of alvimopan in opioid-induced bowel dysfunction (OIBD) (4 arms), sponsored by Merck & Co. Primary endpoint: Change in weekly spontaneous complete bowel movement (SCBM) frequency. Started Oct 2003; status: completed.
02
Drugs
alvimopan
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on NCT00101998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101998.